)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
BiomX (PHGE) investor relations material
BiomX Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Advanced clinical programs for BX004 (cystic fibrosis with Pseudomonas aeruginosa) and BX011 (diabetic foot infections), with significant regulatory engagement and progress in Q3 2025; BX004 and BX011 prioritized, and BX011's Phase 2a trial planning underway, subject to financial resources.
BX004 Phase 2b trial began dosing but faced a temporary FDA clinical hold in the U.S. due to nebulizer device concerns, not the drug itself; European sites continue enrollment without interruption.
BX011 program received positive FDA feedback, confirming a clear path toward BLA submission and no additional non-clinical studies required; BX004 and BX011 received constructive FDA feedback outlining development pathways.
Completed the acquisition of Adaptive Phage Therapeutics (APT) in March 2024, expanding the clinical pipeline.
Ongoing collaboration with the U.S. Defense Health Agency (DHA) for BX011, with $40 million in support to date and potential for future expansion into combat wound indications.
Financial highlights
Cash and restricted cash as of September 30, 2025, was $8.1 million, down from $18 million at year-end 2024, mainly due to operating activities.
Research and development expenses were $6.1 million in Q3 2025, down from $7.3 million in Q3 2024, reflecting workforce reduction and lower manufacturing costs.
General and administrative expenses were $2.4 million in Q3 2025, down from $3.2 million year-over-year.
Net loss was $9.2 million in Q3 2025 versus net income of $9.6 million in Q3 2024, mainly due to changes in fair value of warrants from March 2024 financing.
Net cash used in operating activities for the first nine months of 2025 was $22 million, compared to $30.7 million in the same period of 2024.
Outlook and guidance
Cash runway expected to fund operations into Q1 2026; additional capital will be needed for continued development.
BX004 Phase 2b data readout anticipated in Q1 2026; feedback on FDA clinical hold expected imminently.
BX011 to advance pending financial resources and ongoing DHA discussions; regulatory clarity supports rapid progression.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BiomX earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage